Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells

Molecular Cancer Research

Volumn 1, Issue 4, 2003, Pages 300-311

  Hodges, Leslie C ^a   Cook, Jennifer D ^a   Lobenhofer, Edward K ^b   Li, Leping ^b   Bennett, Lee ^b   Bushel, Pierre R ^b   Aldaz, C Marcelo ^a   Afshari, Cynthia A ^b   Walker, Cheryl Lyn ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; CYCLIN E; ESTROGEN; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FRA 1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CONTROLLED STUDY; DNA CONTENT; DNA FINGERPRINTING; DNA MICROARRAY; DNA PROBE; DRUG MECHANISM; DRUG RESISTANCE; GENE; GENE A2; GENE CDC25A; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE STK15; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; ONCOGENE C FOS; ONCOGENE MYB; ONCOGENE MYC; PHYLOGENETIC TREE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ESTROGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TAMOXIFEN; TIME FACTORS;

EID: 0037293531     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
2. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 90: 1371-1388, 1998.
3. Howe, S. R., Gottardis, M. M., Everitt, J. I., and Walker, C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology, 136: 4996-5003, 1995.
4. Walker, C. L., Burroughs, K. D., Davis, B., Sowell, K., Everitt, J. I., and Fuchs-Young, R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J. Soc. Gynecol. Invest., 7: 249-256, 2000.
5. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988.
6. Satyaswaroop, P. G., Zaino, R. J., and Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res., 44: 4006-4010, 1984.
7. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and DeMets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. N. Engl. J. Med., 326: 852-856, 1992.
8. Guetta, V., Lush, R. M., Figg, W. D., Waclawiw, M. A., and Cannon, R. O., III. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am. J. Cardiol., 76: 1072-1073, 1995.
9. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA, 95: 2920-2925, 1998.
10. Shang, Y. and Brown, M. Molecular determinants for the tissue specificity of SERMs. Science, 295: 2465-2468, 2002.
11. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell, 103: 843-852, 2000.
12. Metzger, D., Ali, S., Bornert, J. M., and Chambon, P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem., 270: 9535-9542, 1995.
13. Tzukerman, M. T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M. G., Stein, R. B., Pike, J. W., and McDonnell, D. P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol., 8: 21-30, 1994.
14. Kirkland, J. L., Murthy, L., and Stancel, G. M. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus. Mol. Pharmacol., 43: 709-714, 1993.
15. Chen, H., Tritton, T. R., Kenny, N., Absher, M., and Chiu, J. F. Tamoxifen induces TGF-β 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J. Cell Biochem., 61: 9-17, 1996.
16. May, F. E., Johnson, M. D., Wiseman, L. R., Wakeling, A. E., Kastner, P., and Westley, B. R. Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J. Steroid Biochem., 33: 1035-1041, 1989.
17. Elgort, M. G., Zou, A., Marschke, K. B., and Allegretto, E. A. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α 1 promoter via a novel sequence. Mol. Endocrinol., 10: 477-487, 1996.
18. Clarke, R., Skaar, T. C., Bouker, K. B., Davis, N., Lee, R., Welch, J. N., and Leonessa, F. Cellular and molecular pharmacology of antiestrogen resistance. J. Steroid Biochem. Mol. Biol., 76: 71-84, 2001.
19. Chen, Y. Ratio-based decisions and the quantitative analysis of cDNA microarray images. J. Biomed. Optics, 2(4): 364-374, 1997.
20. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.
21. Osborne, C. K., Boldt, D. H., Clark, G. M., and Trent, J. M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res., 43: 3583-3585, 1983.
22. Planas-Silva, M. D. and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.
23. Nephew, K. P., Polek, T. C., Akcali, K. C., and Khan, S. A. The antiestrogen tamoxifen induces c-fos and jun-B, but not c-jun or jun-D, protooncogenes in the rat uterus. Endocrinology, 133: 419-422, 1993.
24. Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M., Beato, M., Sica, V., Bresciani, F., and Weisz, A. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
25. Sabbah, M., Courilleau, D., Mester, J., and Redeuilh, G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. USA, 96: 11217-11222, 1999.
26. Grandori, C., Cowley, S. M., James, L. P., and Eisenman, R. N. The Myc/ Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol., 16: 653-699, 2000.
27. Cavailles, V., Dauvois, S., L'Horset, F., Lopez, G., Hoare, S., Kushner, P. J., and Parker, M. G. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J., 14: 3741-3751, 1995.
28. Philips, A., Teyssier, C., Galtier, F., Rivier-Covas, C., Rey, J. M., Rochefort, H., and Chalbos, D. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol. Endocrinol., 12: 973-985, 1998.
29. Hanna, I. H., Dawling, S., Roodi, N., Guengerich, F. P., and Parl, F. F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymerphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 60: 3440-3444, 2000.
30. Montano, M. M. and Katzenellenbogen, B. S. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc. Natl. Acad. Sci. USA, 94: 2581-2586, 1997.
31. Montano, M. M., Wittmann, B. M., and Bianco, N. R. Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity. J. Biol. Chem., 275: 34306-34313, 2000.
32. Li, L., Weinberg, C. R., Darden, T. A., and Pedersen, L. G. Gene selection for sample classification based on gene expression data: study of sensitivity to choice of parameters of the GA/KNN method. Bioinformatics, 17: 1131-1142, 2001.
33. Foster, J. S., Henley, D. C., Ahamed, S., and Wimalasena, J. Estrogens and cellcycle regulation in breast cancer. Trends Endocrinol. Metab., 12: 320-327, 2001.
34. Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J., 13: 1549-1556, 1994.
35. Oh, I. H. and Reddy, E. P. The myb gene family in cell growth, differentiation and apoptosis. Oncogene, 18: 3017-3033, 1999.
36. Baker, V. L., Draper, M., Paul, S., Allerheiligen, S., Giant, M., Shifren, J., and Jaffe, R. B. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J. Clin. Endocrinol. Metab., 83: 6-13, 1998.
37. Prall, O. W., Rogan, E. M., Musgrove, E. A., Watts, C. K., and Sutherland, R. L. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol., 18: 4499-4508, 1998.
38. Musgrove, E. A., Sarcevic, B., and Sutherland, R. L. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J. Cell. Biochem., 60: 363-378, 1996.
39. Lukas, J., Bartkova, J., and Bartek, J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol., 16: 6917-6925, 1996.
40. Watts, C. K., Sweeney, K. J., Warlters, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res. Treat., 31: 95-105, 1994.
41. Watts, C. K., Brady, A., Sarcevic, B., dcFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
42. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F., Blamey, R. W., Musgrove, E. A., Nicholson, R. I., and Sutherland, R. L. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin. Cancer Res., 2: 923-928, 1996.
43. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature, 411: 1017-1021, 2001.
44. Kenny, F. S., Hui, R., Musgrove, E. A., Gee, J. M., Blamey, R. W., Nicholson, R. I., Sutherland, R. L., and Robertson, J. F. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res., 5: 2069-2076, 1999.
45. Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H. L., Munishkin, A., Beauheim, C., Harvey, S., Ethier, S. P., and Johnson, P. H. Identification of gone expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res., 61: 5168-5178, 2001.
46. Milde-Langosch, K., Bamberger, A. M., Methner, C., Rieck, G., and Loning, T. Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/ WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int. J. Cancer, 87: 468-472, 2000.
47. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., Draper, M., and Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [sec comments]. N. Engl. J. Med., 337: 1641-1647, 1997.
48. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J., Gluer, C. C., Krucger, K., Cohen, F. J., Eckert, S., Ensrud, K. E., Avioli, L. V., Lips, P., and Cummings, S. R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 282: 637-645, 1999.
49. Lippman, S. M., Lee, J. J., and Sabichi, A. L. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst., 90: 1514-1528, 1998.
50. Dunn, B. K. and Ford, L. G. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J., 7: 144-157, 2001.
51. Nicholls, H. Aromatase inhibitors continue their ATAC on tamoxifen. Trends Mol. Med., 8: S12-S13, 2002.
52. Nuwaysir, E. F., Bittner, M., Trent, J., Barrett, J. C., and Afshari, C. A. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog., 24: 153-159, 1999.